Hyperion Surgical to showcase IVY at AVA 2026 and ACEP26

Hyperion Surgical will demo its IVY intelligent vascular access platform at two October conferences in Grapevine, Texas, and Chicago. The company says the system is designed to address difficult IV placement by combining imaging, AI-assisted targeting and robotic catheter placement.

Why it matters: - Difficult IV access can lead to repeated attempts, long waits for specialists and delayed treatment. - Hyperion Surgical is pitching IVY as a workflow tool, not just a visualization device, for clinicians handling hard-to-access veins. - The company is targeting conference audiences that influence vascular access practice and emergency care operations.

What happened: - Hyperion Surgical will showcase the IVY intelligent vascular access platform at AVA 2026 and ACEP26 in October. - AVA 2026 runs Oct. 2-4 at the Gaylord Texan Resort & Convention Center in Grapevine, Texas. - ACEP26 runs Oct. 5-8 at McCormick Place Convention Center in Chicago. - Hyperion will host an exhibit at Booth 223 at AVA 2026. - Hyperion will offer digital demonstrations at Booth 3324 at ACEP26. - Dr. Eric Peterson, Hyperion Surgical’s CEO and founder, will be available at both conferences to discuss the platform.

The details: - IVY combines real-time imaging, AI-assisted vessel targeting and clinician-controlled robotic catheter placement. - The platform is designed to standardize peripheral vascular access. - Hyperion says the goal is to improve outcomes for patients with difficult-to-access veins. - The company says the system is intended to give clinicians more confidence, speed care and reduce repeated attempts. - During AVA 2026, Matt Ostroff, MSN, APN, VABC, vascular access coordinator/APN at St. Joseph's University Health, will present "The 3 A.M. Problem: What Happens to Vascular Access When We're Not There" on Sunday, Oct. 4, from 10:30-10:50 a.m. in the Longhorn Exhibition Floor, Vascular Access Theater. - Ostroff’s session will focus on challenges that arise when vascular access expertise is not immediately available and the need for more consistent access capabilities across shifts and care settings. - Dr. Peterson said the platform is meant to close a gap in scalable, expert-level vascular access. - Dr. Peterson also said IVY is designed to change the paradigm of difficult vascular access. - Hyperion describes IVY as an all-in-one portable platform. - Hyperion Surgical says the platform is under development and has not been reviewed or cleared by the U.S. Food and Drug Administration. - IVY is not available for sale. - Hyperion Surgical says the technology is focused on transforming difficult IV access, a challenge marked by high variability and failure rates. - The company says its mission is to turn difficult IV access into a more reliable and consistent outcome for patients and clinicians. - More information is available on the company’s website and LinkedIn.

Between the lines: - The company is using two major clinical meetings to build visibility with vascular access specialists and emergency physicians. - The emphasis on workflow suggests Hyperion wants to frame IVY as a systems solution, not a single-device upgrade. - The FDA status and sale restrictions mean the platform remains in an early stage, so the conference demos are primarily about education and positioning.

What's next: - Hyperion will continue showing IVY to clinicians at AVA 2026 and ACEP26 throughout early October. - The company is likely to keep building awareness while the platform remains in development and awaits regulatory review. - Further product or regulatory updates will determine when IVY can move beyond demonstrations and into clinical use.

The bottom line: - Hyperion Surgical is trying to turn difficult IV placement into a more standardized, technology-assisted process, with two October conference appearances serving as its biggest public showcase to date.